YM-348

YM-348
(IUPAC) ime
	(2S)-1-(7-ethyl-1H-furo[2,3-g]indazol-1-il)propan-2-amin
Klinički podaci
Identifikatori
ATC kod	?
Hemijski podaci
Formula	C14H17N3O
Mol. masa	243,304 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C14H17N3O/c1-3-11-6-12-13(18-11)5-4-10-7-16-17(14(10)12)8-9(2)15/h4-7,9H,3,8,15H2,1-2H3/t9-/m0/s1 ; Key: QLOOWOVVZLBYHU-VIFPVBQESA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

YM-348 je lek sa indazolnim osnovom koji deluje kao potentan i selektivan agonist 5-HT_2C receptor, sa EC₅₀ vrednošću od 1 nM i 15x selektivnošću u odnosu na 5-HT_2A. On je umereno selektivan 3x u odnosu na blisko srodni 5-HT_2B receptor.^[1]^[2] On ispoljava termogeno i anoreksično dejsto u životinjskim studijama, što ga čini potencijalno korisnim u lečenju gojaznosti.^[3]^[4]^[5]^[6]

Povezano

Reference

↑ Kimura, Y; Hatanaka, K; Naitou, Y; Maeno, K; Shimada, I; Koakutsu, A; Wanibuchi, F; Yamaguchi, T (2004). „Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist”. European journal of pharmacology 483 (1): 37–43. PMID 14709324.
↑ Shimada, I; Maeno, K; Kazuta, K; Kubota, H; Kimizuka, T; Kimura, Y; Hatanaka, K; Naitou, Y i dr.. (2008). „Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo2,3-gindazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists”. Bioorganic & medicinal chemistry 16 (4): 1966–82. DOI:10.1016/j.bmc.2007.10.100. PMID 18035544.
↑ Hayashi A, Sonoda R, Kimura Y, Takasu T, Suzuki M, Sasamata M, Miyata K (2004). „Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats”. Brain research 1011 (2): 221–7. DOI:10.1016/j.brainres.2004.03.032. PMID 15157808.
↑ Smith, BM; Thomsen, WJ; Grottick, AJ (2006). „The potential use of selective 5-HT2C agonists in treating obesity”. Expert opinion on investigational drugs 15 (3): 257–66. DOI:10.1517/13543784.15.3.257. PMID 16503763.
↑ Nilsson, BM (2006). „5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents”. Journal of medicinal chemistry 49 (14): 4023–34. DOI:10.1021/jm058240i. PMID 16821762.
↑ Wacker, DA; Miller, KJ (2008). „Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases”. Current opinion in drug discovery & development 11 (4): 438–45. PMID 18600561.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Kimura, Y; Hatanaka, K; Naitou, Y; Maeno, K; Shimada, I; Koakutsu, A; Wanibuchi, F; Yamaguchi, T (2004). „Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist”. European journal of pharmacology 483 (1): 37–43. PMID 14709324.

[2] Shimada, I; Maeno, K; Kazuta, K; Kubota, H; Kimizuka, T; Kimura, Y; Hatanaka, K; Naitou, Y i dr.. (2008). „Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo2,3-gindazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists”. Bioorganic & medicinal chemistry 16 (4): 1966–82. DOI:10.1016/j.bmc.2007.10.100. PMID 18035544.

[3] Hayashi A, Sonoda R, Kimura Y, Takasu T, Suzuki M, Sasamata M, Miyata K (2004). „Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats”. Brain research 1011 (2): 221–7. DOI:10.1016/j.brainres.2004.03.032. PMID 15157808.

[4] Smith, BM; Thomsen, WJ; Grottick, AJ (2006). „The potential use of selective 5-HT2C agonists in treating obesity”. Expert opinion on investigational drugs 15 (3): 257–66. DOI:10.1517/13543784.15.3.257. PMID 16503763.

[5] Nilsson, BM (2006). „5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents”. Journal of medicinal chemistry 49 (14): 4023–34. DOI:10.1021/jm058240i. PMID 16821762.

[6] Wacker, DA; Miller, KJ (2008). „Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases”. Current opinion in drug discovery & development 11 (4): 438–45. PMID 18600561.

[1]